Oruka Therapeutics (NASDAQ:ORKA) saw its stock soar 20% on Tuesday following the release of promising interim results from its Phase 1 trial of ORKA-001, a long-acting IL-23p19 antibody for treating plaque psoriasis.
The company reported that ORKA-001 demonstrated an approximate half-life of 100 days, more than three times longer than that of risankizumab, a competitor. This extended duration suggests the potential for once-yearly dosing, offering a significant advantage over existing therapies that require more frequent administration.
Data presented at the European Academy of Dermatology and Venerology Congress in Paris indicated the drug was well-tolerated at all tested dose levels, with a safety profile consistent with the IL-23p19 class. The pharmacokinetic findings suggest ORKA-001 could achieve drug exposures conducive to higher efficacy and prolonged remission periods without treatment.
“ORKA-001’s approximately 100-day half-life exceeded our expectations and has the potential to enable multiple ’upside’ scenarios for the program,” said Lawrence Klein, PhD, CEO of Oruka. “We are increasingly confident that ORKA-001 can redefine the standard of care in this important disease.”
Oruka is now enrolling patients in its EVERLAST-A Phase 2a trial, with initial results anticipated in the second half of 2026. The company also plans to launch the EVERLAST-B dose-ranging Phase 2b trial in the first half of 2026.
Additionally, Oruka announced it has secured roughly $180 million through a private investment in public equity (PIPE) financing led by Viking Global Investors, with participation from both new and existing investors. The funds will support research and development initiatives and general corporate operations.
Oruka Therapeutics stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.